Literature DB >> 26256699

Anti-inflammatory effects of vina-ginsenoside R2 and majonoside R2 isolated from Panax vietnamensis and their metabolites in lipopolysaccharide-stimulated macrophages.

Jin-Ju Jeong1, Thi Hong Van Le2, Sang-Yun Lee1, Su-Hyeon Eun1, Minh Duc Nguyen2, Jeong Hill Park3, Dong-Hyun Kim4.   

Abstract

Panax vietnamensis Ha et Grushv., with its main constituents vina-ginsenoside R2 (VR2) and majonoside R2 (MR2), is used in traditional folk medicine in the hill tribes of Vietnam for anti-fatigue, anti-inflammatory, and life-saving purposes. In a preliminary study, VR2 and MR2 were shown to be metabolized to pseudoginsenoside RT4 (PRT4) and ocotillol by human gut microbiota. Therefore, we measured the anti-inflammatory effects of VR2, MR2, and their metabolites in lipopolysaccharide (LPS)-stimulated mouse peritoneal macrophages. Among these ginsenosides, only VR2 exhibited cytotoxicity against peritoneal macrophages. MR2, PRT4, and ocotillol inhibited LPS-stimulated transcription factor (NF)-κB activation, and expression of the proinflammatory cytokines tumor necrosis factor-α and interleukin (IL)-1. However, these ginsenosides did not inhibit peptidoglycan-induced NF-κB activation in the macrophages. These three ginsenosides also inhibited LPS-stimulated cyclooxygenase-2 and inducible NO synthase expression, and phosphorylation of NF-κB signal molecules IL-1 receptor-associated kinase 1 and tumor growth factor-β-activated kinase 1 in peritoneal macrophages. Treatment with either PRT4 or ocotillol inhibited the Alexa Fluor 488-conjugated LPS-mediated shift of macrophages, as observed by flow cytometry. They also potently inhibited the binding of LPS to TLR4 on peritoneal macrophages, both with and without transfected MyD88 siRNA. Among the tested ginsenosides, ocotillol exhibited the strongest inhibitory effect on inflammation in LPS-stimulated macrophages via the NF-κB signaling pathway. Based on these findings, orally administered VR2 and MR2 of P. vietnamensis may be metabolized to ocotillol via PRT4, and the metabolites, particularly ocotillol, may inhibit inflammation by inhibiting the binding of LPS to TLR4 on macrophages.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inflammation; Macrophage; Majonoside R2; Ocotillol; Panax vietnamensis; Vina-ginsenoside R2

Mesh:

Substances:

Year:  2015        PMID: 26256699     DOI: 10.1016/j.intimp.2015.07.025

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  In silico studies for the interaction of tumor necrosis factor-alpha (TNF-α) with different saponins from Vietnamese ginseng (Panax vietnamesis).

Authors:  Oanh T P Kim; Manh D Le; Hoang X Trinh; Hai V Nong
Journal:  Biophys Physicobiol       Date:  2016-07-14

Review 2.  Discovery, semisynthesis, biological activities, and metabolism of ocotillol-type saponins.

Authors:  Juan Liu; Yangrong Xu; Jingjing Yang; Wenzhi Wang; Jianqiang Zhang; Renmei Zhang; Qingguo Meng
Journal:  J Ginseng Res       Date:  2017-01-13       Impact factor: 6.060

Review 3.  Gut microbiota-mediated pharmacokinetics of ginseng saponins.

Authors:  Dong-Hyun Kim
Journal:  J Ginseng Res       Date:  2017-04-28       Impact factor: 6.060

Review 4.  Recent Advances in the Semisynthesis, Modifications and Biological Activities of Ocotillol-Type Triterpenoids.

Authors:  Yucheng Cao; Kaiyi Wang; Si Xu; Lingtan Kong; Yi Bi; Xiaopeng Li
Journal:  Molecules       Date:  2020-11-27       Impact factor: 4.411

Review 5.  Progress on the Elucidation of the Antinociceptive Effect of Ginseng and Ginsenosides in Chronic Pain.

Authors:  Mei-Xian Li; Qian-Qi Wei; Huan-Jun Lu
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

6.  Increase in Protective Effect of Panax vietnamensis by Heat Processing on Cisplatin-Induced Kidney Cell Toxicity.

Authors:  Kim Long Vu-Huynh; Thi Hong Van Le; Huy Truong Nguyen; Hyung Min Kim; Ki Sung Kang; Jeong Hill Park; Minh Duc Nguyen
Journal:  Molecules       Date:  2019-12-17       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.